TABLE 4.
Receiving treatment by provider attitudes and hospital climate
| Variable | Antenatal corticosteroid for fetal lung maturity (n = 500 eligible),a n (%) | Progesterone for prevention of preterm birth (n = 753 eligible),b n (%) | Magnesium sulfate for neuroprotection (n = 181 eligible),c n (%) |
|---|---|---|---|
| Provider stated that they prescribe intervention in practice (intent) | |||
| No | 2 (66.7) | 3 (10.3)d | 3 (37.5)d |
| Yes | 461 (92.8) | 289 (39.9)d | 126 (72.8)d |
| Provider was satisfied with their knowledge of the intervention | |||
| No | 27 (100.0) | 29 (28.4)d | 30 (65.2) |
| Yes | 436 (92.2) | 263 (40.5)d | 99 (73.3) |
| Provider rated the quality of the evidence for the intervention as above average to excellent | |||
| No | 7 (87.5) | 35 (24.5)d | 53 (69.7) |
| Yes | 456 (92.7) | 257 (42.3)d | 75 (72.1) |
| Provider perceived barriers to their patients’ receiving the intervention | |||
| No | 398 (92.1) | 56 (35.2) | 93 (73.2) |
| Yes | 63 (95.5) | 236 (39.9) | 33 (66.0) |
| Financial | |||
| No | 461 (92.6) | 143 (36.3) | 125 (71.0) |
| Yes | 0 (0.0) | 149 (41.9) | 1 (100.0) |
| Fear of birth defects | |||
| No | 457 (92.7) | 263 (38.0) | 126 (71.2) |
| Yes | 4 (80.0) | 29 (50.9) | 0 (0.0) |
| Fear of side effects | |||
| No | e | e | 99 (73.3) |
| Yes | e | e | 27 (64.3) |
| Fear of injections | |||
| No | 439 (92.4) | 173 (40.9) | e |
| Yes | 22 (95.7) | 119 (36.4) | e |
| Difficulty with hospital or pharmacy drug delivery | |||
| No | 454 (92.7) | 235 (41.5)d | 126 (71.2) |
| Yes | 7 (87.5) | 57 (31.0)d | 0 (0.0) |
| Difficulty arranging injection | |||
| No | e | 222 (40.3) | e |
| Yes | e | 70 (35.2) | e |
| Poor compliance | |||
| No | 440 (92.2) | 231 (39.5) | e |
| Yes | 21 (100.0) | 61 (37.0) | e |
| Poor patient understanding of drug benefits | |||
| No | 445 (92.5) | 254 (39.6) | 112 (70.4) |
| Yes | 16 (94.1) | 38 (34.9) | 14 (77.8) |
| Team Climate Inventory score | |||
| Quartile 1 | 90 (93.8) | 56 (33.7) | 23 (69.7) |
| Quartile 2 | 104 (95.4) | 81 (44.8) | 26 (63.4) |
| Quartile 3 | 127 (90.7) | 73 (39.9) | 40 (76.9) |
| Quartile 4 | 120 (90.2) | 72 (38.3) | 33 (71.7) |
Patients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks of gestation and delivered 4 or more hours after admission;
Patients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated by a first- or second-trimester ultrasound or had assisted reproductive technology;
Patients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of gestation, did not have gestational hypertension or preeclampsia, and delivered 4 or more hours after admission;
Statistically significant χ2 or Fisher exact test (P < .05);
The survey did not ascertain this information for this particular intervention.